Cephorum 250mg Film Coated Tablets

Main information

  • Trade name:
  • cephorum comprimé pelliculé 250 mg
  • Pharmaceutical form:
  • Film coated tablet
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • cephorum comprimé pelliculé 250 mg
    France
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • Cefalexin
  • Therapeutic area:
  • Dogs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0411/001
  • Authorization date:
  • 21-12-2011
  • EU code:
  • UK/V/0411/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Revised:February2012

AN:00045/2011

Page1of6

SUMMARYOFPRODUCTSCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Cephorum250mgfilm-coatedtabletsfordogs

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachtabletcontains:

Activeingredient:

Cefalexin 250mg

ascefalexinmonohydrate 263mg

Excipients:

Titaniumdioxide(E171) 0.55mg

Excipientqsp1tabletof355mg

Forafulllistofexcipients,seesection6.1

3. PHARMACEUTICALFORM

Film-coatedtablet

Round,whitetoyellowish,biconvextablet,scoredononeside.‘CX’is

imprintedabovethescoreline,‘250’isimprintedbelowthescoreline.

Thetabletsarenotdivisible.

4. CLINICALPARTICULARS

4.1 Targetspecies

Dogs

4.2 Indicationsforuse,specifyingthetargetspecies

Theproductisindicatedforthetreatmentofurinarytractinfectionsindogs

causedbyKlebsiellapneumoniaeandforthetreatmentofbacterialskin

infectionsindogs,whensusceptibleorganismsarepresent.

4.3 Contra-indications

Donotuseincasesofknownhypersensitivitytotheactivesubstance,to

othercephalosporins,toothersubstancesoftheβ-lactamgrouportoanyof

theexcipients.

Donotuseinrabbits,gerbils,guineapigsandhamsters.

4.4 Specialwarningsforeachtargetspecies

None

Revised:February2012

AN:00045/2011

Page2of6

4.5 Specialprecautionsforuse

i. Specialprecautionsforuseinanimals

Useoftheproductshouldbebasedonsusceptibilitytestingandtake

intoaccountofficialandlocalantimicrobialpolicies.

UseoftheproductdeviatingfromtheinstructionsgivenintheSPC

mayincreasetheprevalenceofbacteriaresistanttocefalexinandmay

decreasetheeffectivenessoftreatmentwithpenicillins,dueto

potentialcross-resistance.

Incaseofanallergicreaction,treatmentshouldbewithdrawn.

Aswithotherantibioticswhichareexcretedmainlybythekidneys,

unnecessaryaccumulationmayoccurinthebodywhenrenalfunction

isimpaired.Incasesofknownrenalinsufficiencythedoseshouldbe

reduced,antimicrobialsknowntobenephrotoxicshouldnotbe

administeredconcurrentlyandtheproductshouldbeusedonly

accordingtoarisk/benefitassessmentbytheresponsibleveterinarian.

ii. Specialprecautionsforthepersonadministeringtheveterinary

medicinalproducttoanimals

Penicillinsandcephalosporinsmaycausehypersensitivity(allergy)

followinginjection,inhalation,ingestionorskincontact.

Hypersensitivitytopenicillinsmayleadtocross-reactionsto

cephalosporinsandviceversa.Allergicreactiontothesesubstances

mayoccasionallybeserious.

1.Donothandlethisproductifyouknowyouaresensitised,orif

youhavebeenadvisednottobeincontactwithsuch

preparations.

2.Handlethisproductwithgreatcaretoavoidexposuretakingall

recommendedprecautions.

3.Ifyoudevelopsymptomsfollowingexposure,suchasaskin

rash,youshouldseekmedicaladviceandshowthedoctorthis

warning.Swellingoftheface,lipsoreyesordifficultyin

breathingaremoreserioussymptomsandrequireurgent

medicalattention.Incaseofaccidentalingestion,seekmedical

attentionimmediatelyshowingthephysicianthisinformation.

Washhandsafteruse.

4.6 Adversereactions(frequencyandseriousness)

Vomitingand/ordiarrhoeahavebeenobservedindogs.Inrarecases

hypersensitivitycanoccur.Incasesofhypersensitivityreactionsthe

treatmentshouldbestopped.

Revised:February2012

AN:00045/2011

Page3of6

4.7 Useduringpregnancy,lactationorlay

Thesafetyoftheveterinarymedicinalproducthasnotbeenestablishedin

bitchesduringpregnancyandlactation.Useonlyaccordinglytothe

benefit/riskassessmentbytheresponsibleveterinarian.

4.8 Interactionwithothermedicinalproductsandotherformsofinteraction

Thebactericidalactivityofcephalosporinsisreducedbyconcomitant

administrationofbacteriostaticactingcompounds(macrolides,

sulphonamidesandtetracyclines).

Nephrotoxicitycanbeincreasedwhen1 st

generationcephalosporinsare

combinedwithpolypeptideantibiotics,aminoglycosidesandsomediuretics

(furosemide).

Concomitantusewithsuchactivesubstancesshouldbeavoided.

4.9 Amount(s)tobeadministeredandadministrationroute

Fororaluse.

Therecommendeddoserateis15mgcefalexin/kgbodyweighttwicedaily.

Insevereoracuteconditionstheabovedosemaybesafelydoubledto30

mg/kgorgivenatmorefrequentintervals.

Thetablebelowisintendedasaguidefortherecommendeddoseof15mg

cefalexinperkgbodyweight.Anyincreaseinthedoseshouldbecalculated

case-by-casefortheindividualanimalconcerned.

Bodyweightinkg Numberoftablets

perdose*

12to18 1tablet

19to32 2tablets

33to50 3tablets

*Twodosesperdayshouldbegiven

Toensureacorrectdosagebodyweightshouldbedeterminedasaccurately

aspossibletoavoidunderdosing.

Treatmentforfivedaysisrecommendedbutthismaybeextendedor

shortenedatthediscretionoftheveterinarysurgeon.

Anyincreaseindoseordurationofuse,andanyuseindogslessthan12kg

bodyweight,shouldbeinaccordancewitharisk/benefitassessmentbythe

responsibleveterinarian.

4.10 Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Symptomsofoverdoseincludenausea,vomiting,epigastricdistress,

diarrhoeaandhaematuria.Treatmentshouldbesymptomatic.

4.11 Withdrawalperiod(s)

Notapplicable.

Revised:February2012

AN:00045/2011

Page4of6

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:

Antibacterialsforsystemicuse,Otherbeta-lactamantibacterials,First-

generationcephalosporins

ATCVetCode:QJ01DB01

5.1 Pharmacodynamicproperties

Cefalexin,firstgenerationcephalosporin,inhibitsbacterialcellwallsynthesis

inamannersimilartothepenicillins,andiswidelyconsideredtobe

bactericidalinaction.Itisthoughtthatcefalexinactsbybindingtoand

inactivatinganumberofdifferentpenicillin-bindingproteins(PBPs)located

ontheinneraspectsofthebacterialcellmembrane.Cephalosporinsare

essentiallytime-dependentantibiotics.

Cefalexinisactiveagainstalargespectrumofgram-positiveandgram-

negativebacteria.Thebreakpointsforcefalexi nareusuallydefinedasS≤8

μg/ml,R>32μg/ml.

Theinvitroactivityofcefalexinagainstbacterialisolatesfromskininfections

indogsisasfollows:

Pathogen

MIC

90 (µg/ml)

S.intermedius 0.5to8

S.aureus 2to8

E.coli 2to16

BetahaemolyticStreptococcusspp.(86) 2

TheMIC

valueofcefalexinagainstKlebsiellapneumoniaeisolatedfrom

urinarytractinfectionsindogsis4µg/ml.

Themostprevalentresistancemechanismamonggram-negativebacteriato

cefalexinisduetotheproductionofvariousbeta-lactamases

(cephalosporinase)thatcauseinactivation.Resistanceingram-positive

bacteriaofteninvolvesadecreasedaffinityofthePBPs(penicillin-binding

proteins)forbeta-lactamdrugs.Effluxpumps,extrudingtheantibioticfrom

thebacterialcell,andstructuralchangesinporins(reducingpassivediffusion

ofthedrugthroughthecellwall),maycontributetobacterialresistance.

Cross-resistance(involvingthesameresistancemechanism)existsbetween

antibioticsbelongingtothebeta-lactamgroupduetotheirsimilarstructures.

Thisoccurswithbeta-lactamaseenzymes,structuralchangesinporinsor

variationsineffluxpumps.Co-resistance(involvingdifferentresistance

mechanisms)hasbeenreportedinE.coliduetoaplasmidwithresistance

genes.

Revised:February2012

AN:00045/2011

Page5of6

5.2 Pharmacokineticproperties

Afteroraladministration,60to80%ofcefalexinisabsorbedfromthesmall

intestine.Thedelayreportedbetweenadministrationandbeginningof

absorptionisapproximately20minutesanddifferencesinmeanAUC,Cmax,

andTmaxarenotsignificantlyaffectedbyfoodadministrationconcomitantto

treatmentwithcefalexin.

Doseadministered

(mg/kg) 15

Cmax(µg/ml) 17.6

Tmax(min) 158

AUC(µg.h/ml) 73.5

Halflife(min) 107

Proteinbindingislowat18%.Cefalexiniswidelydistributedintoavarietyof

tissuefluids,includingbile,synovialandpericardialfluid.Thepassageinto

interstitialtissue,asdemonstratedinwoundfluidconcentration,peritoneal

fluidandskinblistersisgenerallygood.

Cefalexinisminimallymetabolizedandprimarilyexcretedviatherenalroute,

around70%ofanoraldoseisexcretedintotheurinein24hoursinthedog.

Itisimportanttonotethatcefalexinconcentrationsobtainedinurinearewell

aboveplasmaconcentrations,andsimilarlyconcentrationsinbilemaybeup

tofourtimeshigher.

6. PHARMACEUTICALPARTICULARS

6.1 Listofexcipients

Titaniumdioxide(E171)

PovidoneK25

Sodiumstarchglycolate(TypeA)

Magnesiumstearate

Macrogol6000

Lactosemonohydrate

Hypromellose

Talc

Peppermintoil

Saccharinsodiumdihydrate

6.2 Incompatibilities

Noneknown.

6.3 Shelflife

Shelflifeoftheveterinarymedicinalproductaspackagedforsalein

polypropylenesecuritainers:4years

Revised:February2012

AN:00045/2011

Page6of6

Shelflifeoftheveterinarymedicinalproductaspackagedforsaleinblister

packs:4years

6.4 Specialprecautionsforstorage

Donotstoreabove30°C.

Protectfromlight.

6.5 Natureandcompositionofimmediatepackaging

Whitepolypropylenesecuritainerswithwhitepolyethylenesnaponcaps

containing50,100or250tablets.

PVC/PVDC –Aluminiumfoilblisterpackscontaining10stripsof10tablets

eachor8stripsof14tabletseach.

Notallpacksizesmaybemarketed.

6.6 Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts,if

appropriate

Anyunusedveterinarymedicinalproductorwastematerialsderivedfrom

suchveterinarymedicinalproductsshouldbedisposedofinaccordancewith

localrequirements.

7. MARKETINGAUTHORISATIONHOLDER

ForumProductsLimited

BetchworthHouse

57-65StationRoad

Redhill

Surrey

RH11DL

UnitedKingdom

8. MARKETINGAUTHORISATIONNUMBER

Vm05928/4004

9. DATEOFFIRSTAUTHORISATION

11June1999

10. DATEOFREVISIONOFTHETEXT

February2012

7-12-2018

Magnesium citrate malate as a source of magnesium added for nutritional purposes to food supplements

Magnesium citrate malate as a source of magnesium added for nutritional purposes to food supplements

Published on: Thu, 06 Dec 2018 The present scientific opinion deals with the assessment of the bioavailability of magnesium, from the proposed nutrient source, magnesium citrate malate (MgCM), when added for nutritional purposes to food supplements. MgCM is a mixed salt consisting of magnesium cations and citrate and malate anions, and with a magnesium content of 12–15%. MgCM is proposed to be used in food supplements that are intended to provide up to 300–540 mg/day magnesium. The data provided demonst...

Europe - EFSA - European Food Safety Authority Publications

3-8-2018

Scientific guideline:  Ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg product-specific bioequivalence guidance, adopted

Scientific guideline: Ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg product-specific bioequivalence guidance, adopted

Ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg product-specific bioequivalence guidance

Europe - EFSA - European Food Safety Authority EFSA Journal

3-8-2018

Scientific guideline:  Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance, adopted

Scientific guideline: Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance, adopted

Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance

Europe - EFSA - European Food Safety Authority EFSA Journal

31-7-2018

Public Notification: Black Rhino 25000 contains hidden drug ingredient

Public Notification: Black Rhino 25000 contains hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use Black Rhino 25000, a product promoted for sexual enhancement. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

31-7-2018

Public Notification: Krazzy Rhino 25000 contains hidden drug ingredient

Public Notification: Krazzy Rhino 25000 contains hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use Krazzy Rhino 25000, a product promoted for sexual enhancement. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

31-7-2018

Public Notification: Gold Rhino 25000 contains hidden drug ingredient

Public Notification: Gold Rhino 25000 contains hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use Gold Rhino 25000, a product promoted for sexual enhancement. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

31-7-2018

Public Notification: Platinum Rhino 25000 contains hidden drug ingredient

Public Notification: Platinum Rhino 25000 contains hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use Platinum Rhino 25000, a product promoted for sexual enhancement. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

10-7-2018

Preventieve HIV-remmers (PrEP) worden verstrekt voor een periode van vijf jaar

Preventieve HIV-remmers (PrEP) worden verstrekt voor een periode van vijf jaar

PrEP wordt binnen een onderzoekssetting voor een periode van vijf jaar verstrekt aan de hoogrisicogroep van mannen die seks hebben met mannen (MSM). Dat heeft minister Bruno Bruins (Medische Zorg) vandaag bekend gemaakt. Op basis van schattingen van het RIVM zullen ongeveer 6500 mannen hiervan gebruik gaan maken en kunnen hiermee  250 hiv-infecties per jaar worden voorkomen. Voor gebruikers gaat een eigen bijdrage gelden van maximaal 25%, dat komt overeen met ongeveer 12 euro per maand. Ook wordt hen gev...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

4-5-2018

Badger Botanicals Recalls Red Suma, Green Suma, Green Hulu 2, And Red Hulu 2 Kratom Supplements Because Of Possible Salmonella Health Risk

Badger Botanicals Recalls Red Suma, Green Suma, Green Hulu 2, And Red Hulu 2 Kratom Supplements Because Of Possible Salmonella Health Risk

Badger Botanicals, LLC of Springville, Utah is recalling Green Suma, Red Suma, Green Hulu 2, and Red Hulu 2 kratom dietary supplements sold directly to consumers via the company website from January 1st, 2018 to April l 12th, 2018 in pouches of 250g, because it has the potential to be contaminated with Salmonella.

FDA - U.S. Food and Drug Administration

21-2-2017

Takeda Pharma A/S recalls batch of Pamol® in packs of 300 film-coated tablets

Takeda Pharma A/S recalls batch of Pamol® in packs of 300 film-coated tablets

Takeda Pharma A/S recalls a batch of Pamol® in packs of 300 film-coated tablets after the discovery of Ibumetin 600 mg containing ibuprofen in some packs. Both types of medicine are used for the treatment of mild pain, but they work in different ways and may cause different adverse reactions.

Danish Medicines Agency

15-1-2014

Revocation of wholesale distribution and manufacturing authorisations granted to Singad Pharma ApS

Revocation of wholesale distribution and manufacturing authorisations granted to Singad Pharma ApS

On 20 December 2013 and on 10 January 2014, the Danish Health and Medicines Authority decided to revoke the section 39 authorisations for wholesale distribution and manufacturing of medicinal products with the authorisation IDs 25081 and 25082 granted to Singad Pharma ApS (company number 255894).

Danish Medicines Agency

30-10-2018

EU/3/14/1250 (Akcea Therapeutics UK Ltd)

EU/3/14/1250 (Akcea Therapeutics UK Ltd)

EU/3/14/1250 (Active substance: Phosphorothioate oligonucleotide targeted to transthyretin) - Transfer of orphan designation - Commission Decision (2018)7282 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/098/13/T/01

Europe -DG Health and Food Safety

6-6-2018

Stocrin (Merck Sharp and Dohme B.V.)

Stocrin (Merck Sharp and Dohme B.V.)

Stocrin (Active substance: efavirenz) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3689 of Wed, 06 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/250/T/113

Europe -DG Health and Food Safety